Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Non-small Cell Lung Cancer: early-phase trial registry
1 of 16 indexed Recurrent Non-small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 1 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Recurrent Non-small Cell Lung Cancer: 16 US clinical trials tracked, 1 recruiting.
Recurrent Non-small Cell Lung Cancer is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 10 of these trials.
Enrollment posture brief
Registry condition recurrent-non-small-cell-lung-cancer
OPEN 1 | RECR 6% | LATE 0 | EARLY 13 | RANK #1060 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Stage IV Pancreatic Cancer (6% recruiting · 16 trials)
Recurrent Non-small Cell Lung Cancer lists 1 open slots (6% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Non-small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Non-small Cell Lung Cancer is recruiting below its size-band peers.
1 of 16 indexed trials (6.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Non-small Cell Lung Cancer research.
National Cancer Institute (NCI) accounts for 10 of 16 trials (62.5%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Non-small Cell Lung Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 16 trials that report a genuine target (sentinel values excluded). 12 of those (75%) plan for fewer than 100 participants.
-
Recurrent Non-small Cell Lung Cancer research is mostly interventional.
16 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
NCT02178163
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
NCT04623775
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Jonsson Comprehensive Cancer Center
NCT01345851
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
H. Lee Moffitt Cancer Center and Research Institute
NCT05681780
Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00085280
APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer
Tragara Pharmaceuticals
NCT00652340
Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00062101
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00087412
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00410904
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00079235
A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00077350
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
National Cancer Institute (NCI)
NCT00118144
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00052338
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
NCT00028535
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00778167
Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
Roswell Park Cancer Institute
NCT01781741
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Non-small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Non-small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Non-small Cell Lung Cancer page
16 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Non-small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Recurrent Non-small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Non-small Cell Lung Cancer condition card totals 16 registered trials; most-linked intervention laboratory biomarker analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.